Clinical Trials Browser

Interventional × Neurofibromatosis 1 × 90 days × Clear all

NCT05849662 2026-04-15

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Phase 1/2 Recruiting

CNSOther hematologic neoplasm

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

NCT01362803 2026-04-14

AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

Phase 1/2 Active not recruiting

99 enrolled 4 FDA

Neurofibromatosis 1, Pain, Neurofibroma, Plexiform

NCT01089101 2026-04-13

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

Phase 1/2 Active not recruiting

Astrocytoma, Neurofibromatosis 1

NCT03190915 2026-04-13

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Phase 2 Active not recruiting

10 enrolled 11 charts

CNSOther hematologic neoplasm

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

NCT03871257 2026-04-13

A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

Phase 3 Active not recruiting

Neurofibromatosis 1

NCT07521657 2026-04-13

NF118

Phase 2 Not yet recruiting

Glioblastoma, Glioma, Neurofibromatosis 1

NCT06507748 2026-04-09

A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)

Phase NA Recruiting

Neurofibromatosis 1, Pain, Neurofibroma, Plexiform

NCT03962543 2026-04-08

ReNeu

Phase 2 Active not recruiting

114 enrolled 25 charts 3 FDA

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT05735717 2026-04-06

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Phase 2 Recruiting

CNSClassical hematologyLymphoidOther hematologic neoplasm

Chromosome 7, monosomy, Anemia, Refractory, with Excess of Blasts, Chromosome Aberrations, Influenza, Human, Neurofibromatosis 1, Leukemia, Myeloid, Acute, beta-Thalassemia, Neoplasm, Residual, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT03975829 2026-04-02

Pediatric Long-Term Follow-up and Rollover Study

Phase 4 Active not recruiting

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

NCT04750928 2026-04-01

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

Phase 1/2 Recruiting

Neurofibromatosis 1

NCT04924608 2026-03-23

KOMET

Phase 3 Active not recruiting

145 enrolled 17 charts 3 FDA

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT06541847 2026-03-20

INSPIRE-NF1

Phase 2 Recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT06188741 2026-03-12

NF114

Phase 2 Recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT06502171 2026-03-12

NF113

Phase 1 Not yet recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT02407405 2026-03-05

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Phase 2 Active not recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT06934928 2026-03-05

Assessing the Efficacy of Repeat, Monthly Treatments of Alexandrite Laser for NF1-associated Cutaneous Neurofibromas (cNFs)

Phase NA Suspended

Neurofibromatosis 1, Neurofibromatoses

NCT07233408 2026-02-27

Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health Literacy

Phase NA Recruiting

Neurofibromatosis 1, Neurofibromatoses

NCT05101148 2026-02-23

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

Phase 1 Active not recruiting

Neurofibromatosis 1

NCT05361811 2026-02-19

Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial

Phase NA Recruiting

CNSDermatologic

Cardiofaciocutaneous syndrome, Legius syndrome, Neurofibromatosis 1, Noonan Syndrome, Genetic Diseases, Inborn, Costello Syndrome

NCT05005845 2026-02-17

NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

Phase 2 Completed

199 enrolled 15 charts

Neurofibromatosis 1

NCT07102394 2026-02-17

Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1

Phase 1 Recruiting

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses

NCT05253131 2026-02-11

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

Phase 2 Not yet recruiting

Neurofibromatosis 1, Sarcoma, Neurofibrosarcoma

NCT04590235 2026-01-30

A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

Phase 1 Active not recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform